Ctrl/Cmd K

Loading stock analysis…

Explore

Stocks
Screener
IPOs
News

Tools

Backtest
Portfolio
Wealth
ITR

Learn

Guides
Methodology

Company

About
Contact
Disclosures
Privacy
Terms

© 2026 Anvest. All rights reserved.

Designed & Engineered in India·harsh@anvest.in

Disclaimer: Anvest provides financial analytics, screening simulations, and planning tools for informational and educational purposes only. Anvest is not a SEBI-registered investment advisor or broker. Nothing herein constitutes investment advice or an offer to buy/sell securities. Full details on methodology and limitations are documented under Disclosures and Terms.

Stocks›Healthcare

Alivus Life Sciences Limited

ALIVUS · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹1,415.30

+₹17.90 (+1.28%)(1D)

₹819.0052 Week Range₹1,499.00

Chart Score AI Profile Fundamentals Technicals Financials Shareholding Peers Filings

Anvest Score

83/100

Valuation

56/100

Quality

82/100

Growth

93/100

Health

100/100

Momentum

91/100

Valuation
56
Quality
82
Growth
93
Health
100
Momentum
91

Loading company profile…

Loading fundamentals…

Loading technical indicators…

Loading financial statement…

Loading shareholding…

Loading peer comparison…

Loading filings…

More Page Context

Research at a glance

Alivus Life Sciences Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹1,415.3

Market cap

₹17,374 Cr

P/E ratio

25.95

P/B ratio

5.21

Dividend yield

Not available

ROE

Not available

RSI 14

62.77

1Y return

Not available

Alivus Life Sciences Limited FAQs

3 topics

ExpandCollapse

Related paths

Peer links appear when comparable names are available.

Open screener Curated screens Backtest ideas

What does the Alivus Life Sciences Limited (ALIVUS) stock page cover?

Alivus Life Sciences Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for ALIVUS?

Alivus Life Sciences Limited is currently shown with a delayed price near ₹1,415.3, P/E 25.95.

Does the ALIVUS page provide investment advice?

No. The ALIVUS page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring

Related insights

CAPLIPOINT

Caplin Point Laboratories Limited · Healthcare

COHANCE

Cohance Lifesciences Limited · Healthcare

SHILPAMED

Shilpa Medicare Limited · Healthcare

Eliminating Look-Ahead Bias in Indian Fundamental Backtests

Understand why using quarter-end dates (like March 31) invalidates fundamental backtests. Learn how Anvest enforces official SEBI filing delays.

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Alivus Life Sciences Limited manufactures and sells chemical and chemical products, pharmaceuticals, and medicinal, chemical, and botanical products. The company generates revenue from these activities.

Drug Manufacturers - Specialty & Generic

Business profile as of 2026-08-25

Business at a Glance

These segments constitute approximately 90% of the entity's turnover.

Revenue growth: +6.9%FY26 growth+5.7%3Y CAGR
EPS growth: +16.1%FY26 growth+6.4%3Y CAGR
CFO / PAT: 1.00×FY26

What Looks Strong

QualityQuality score is supported by healthy return on equity (ROE 16.9%).
Cash FlowOperating cash flow was 1.00× total net profit in FY26.
MarketShareholder returns of +20.9% CAGR over five years.

What to Watch

ValuationShare price has risen ~32% annualised over three years against ~6% profit growth, increasing valuation sensitivity to a growth slowdown.

Reports a single operating segment in its results filings.
The company generates revenue by researching, developing, manufacturing, and marketing a diverse portfolio of specialty and generic pharmaceutical products.
It sells these drugs to hospitals, pharmacies, and healthcare providers, leveraging its manufacturing capabilities and distribution networks.

FY26 (standalone): revenue ₹2,552 cr, up 7% from ₹2,387 cr in FY25; net profit ₹564 cr, up 16% from ₹486 cr in FY25.
FY26 (standalone): operating cash flow ₹565 cr (1.0× net profit); debt/equity 0.01×.
Latest quarter to Sep 2026 (standalone): revenue ₹682 cr (up 16% year on year); net profit ₹197 cr.